Today’s Annals of Oncology and ESMO Open Concomitant publications are available online: www.annalsofoncology.org/concomitant @myesmo.bsky.social #ESMO25

The First Annals of Oncology and ESMO Open Concomitant publications are available online: www.annalsofoncology.org/concomitant @myesmo.bsky.social #ESMO25

Update from the #POSITIVE trial at #ESMO25 - 71-month follow-up showed no increase in recurrence among women who paused treatment to conceive, offering important reassurance for patients and clinicians 👏 🇮🇪 participated, with CTI as national sponsor and Prof Janice Walsh as NLI. #BreastCancer

Another fantastic @myesmo.bsky.social GI oncology podcast about #oligometastatic #gastric cancer is finally out! Please take a moment to 🎧 and share it with your team: soundcloud.com/esmo-podcast...

ESMO 50th Anniversary: Half a Century of Evidence-Based Cancer Care @myesmo.bsky.social oncodaily.com/societies/es... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO

Updates from the ESMO Gastrointestinal Cancers Congress 2025 @myesmo.bsky.social oncodaily.com/insight/esmo... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMOGI25 #GIOnc

🚨 ESMO’s New Global Guidelines for Molecular Tumor Boards (MTBs) 🧬💻 Published in Annals of Oncology, this comprehensive special article by the @myESMO Precision Oncology Working Group delivers international recommendations to standardize MTB structure, quality, and function in clinical practice.

New research in Annals of Oncology shows that a breath-based diagnostic tool—an “electronic nose”—is getting surprisingly close to clinical reality. #lungcancer

📢 New in Annals of Oncology: Final survival results from the #PENELOPEB trial: Palbociclib vs placebo in high-risk HR+/HER2- breast cancer after neoadjuvant chemo. Full paper: www.annalsofoncology.org/article/S092...

📢 Delighted to share a new publication in Annals of Oncology. PEACE III is the first major Phase III trial to combine an ARPI with radiopharmaceutical that showed statistical significance in meeting the primary endpoint.https://ow.ly/SH8K50W1Zct @silkegillessen.bsky.social

Lung cancer detection by electronic nose analysis of exhaled breath: a multi-center prospective external validation study, published in Annals of Oncology. 👉 Read it before your patients: bit.ly/43NzBfO

Potential solid tumor indications for MRD continue to pile up, including new cervical cancer data presented at ASCO and simultaneously published in Annals of Oncology.

👉 Asia Pacific’s oncology spotlight is on you. Submit your abstract for ESMO Asia 2025 by 12 August. Get published in Annals of Oncology and connect with top experts in Singapore, 5–7 December. Your research. Your impact. #ESMOAsia25 🔗 buff.ly/ycEGK9a

An exciting first day of the ESMO Sarcoma and Rare Cancers congress with the launch of ESMO Rare Cancers! Congratulations to the Editorial team on reaching this important milestone. The inaugural issue is online: www.esmorarecancers.org/current

Gutted not to be Geneva 🇨🇭 for #ESMOImmuno24 in person this year 🥹. If you are presenting your work at #ESMOImmuno24, and potentially looking for a home for your research work, please consider submitting to our ESMO IOTECH journal: 🔗 esmoiotech.org

📢👏👏👏👏👏THANKS TO REFEREES 2024: The Editor-in-Chief and Associate Editors of Annals of Oncology would like to extend their sincere appreciation to all those who have worked as referees for the journal. www.sciencedirect.com/science/arti... #ESMO

New Annals of Oncology article in press: The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial www.sciencedirect.com/science/arti... #ESMO

📖 #AnnalsOfOncology #DYK Alongside Annals of Oncology, ESMO’s portfolio includes ESMO Open, Immuno-Oncology and Technology, ESMO Gastrointestinal Oncology, ESMO Real World Data and Digital Oncology & ESMO Rare Cancers to provide comprehensive insights across #Oncology 🔗 ow.ly/exiT50UgvZl

I'm delighted to announce that ESMO Rare Cancers is now open for submissions! For more information on our aims & scope, please have a look at the introductory Editorial by the Co-Editors-in-Chief #ESMO #Oncology www.esmorarecancers.org/article/S305...

📖 #AnnalsOfOncology #MilestonesMonday: In 2008 Annals_ of Oncology became the official journal of the Japanese Society of Medical Oncology expanding its global influence and matching the society’s global expansion. #ESMO 🔗 ow.ly/9LCT50U8U9f

📖 @Annals of Oncology marks 35 years with Prof. David Kerr, Editor-in-Chief (2000-2009). He reflects on the journal’s growth, challenges, and offers advice for emerging researchers. Read the full interview 🔗 ow.ly/Osug50UbMfe

👉 Watch Prof. Gietema, Dr. Trama, Dr. Valverde & Prof. Girard discuss how collaboration drives better outcomes for rare cancer patients. Submit your abstract for ESMO Sarcoma and Rare Cancers 2025 by 7 Jan & join the conversation! #ESMORareCancers25 🔗 ow.ly/bxph50Ua6zJ

📖 To mark the 35th anniversary of Annals of Oncology, Prof. Cavalli, founding Editor-in-Chief (1989-2000), reflects on the journal’s origins, challenges, and its impact on advancing oncology. #ESMO 🔗 ow.ly/uC6R50UbLJE

📖 Have you read "Exosome-based liquid biopsies in cancer: opportunities and challenges", one of Annals of Oncology’s top-cited papers of 2023? #CancerResearch #AnnalsOfOncology 🔗 ow.ly/9AYe50U7MNP

📖 To mark 35 years of Annals of Oncology, putting a 2023 top-cited paper in the spotlight: "High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types." #AnnalsOfOncology 🔗 ow.ly/pbE650U7MPt

Congratulations to IOTECH Editor in Chief Prof John Haanen on receiving the 2024 KNAW Bob Pinedo Cancer Care Award. www.esmoiotech.org #ESMO

#ESMOImmuno24: 🚨 Last Chance to Save on Registration 🚨 Exciting times ahead! Late-breaking abstract authors-titles are now online! 👉 Head to the programme to see the science you can look forward to and register today! Hope to see you there! 🔗https://ow.ly/QvNu50U483r

👉 Discover how to implement the ESMO Guidelines in real-world clinical scenarios and contribute to a richer learning experience by submitting your questions to the experts. 🔗 ow.ly/3v8h50U67lG

Annals of Oncology received its first impact factor in 1994, a key achievement in #oncology publishing. 3 decades later the IF stands at 56.7, ranking 4th in oncology www.sciencedirect.com/journal/anna...

📖 #AnnalsOfOncology #DYK In December 1990 Annals of Oncology published its first ESMO Congress abstract book, featuring 481 abstracts from 25 countries. 🔗 ow.ly/EZc450U6NfO

📖 #AnnalsOfOncology #MilestonesMonday: In 2000, David Kerr succeeded Franco Cavalli to become the second Editor-in-Chief of Annals of Oncology shaping its next decade of impactful publications. ow.ly/NiT850U6N8i

Check out this new study published in ESMO Open looking at clinical outcomes of early stage #TripleNegativeBreastCancer after neoadjuvant chemotherapy according to #HER2low status☆ www.sciencedirect.com/science/arti... @ptarantinomd.bsky.social

Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapy - published in ESMO Open #precisionmedicine www.esmoopen.com/article/S205...

🎧Article of the month: listen to the new podcast in which Annals of Oncology Editor-in-Chief Tom Powles discusses the ENGOT-en11/GOG-3053/KEYNOTE-B21 trial with Dr Toon Van Gorp of the Leuven Cancer Institute, Belgium. soundcloud.com/esmo-podcast...

New Annals of Oncology article in press: A phase III randomized trial on the addition of a contact x-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial annalsofoncology.org/retrieve/pii...

📖 #AnnalsOfOncology #MilestonesMonday: The very first issue of Annals of Oncology was published in January 1990 with Franco Cavalli as founding Editor-in-Chief. Since then, it’s been a key resource for Oncology Research and practice worldwide. 🔗 ow.ly/wHRu50U6MWV

📖 ESMO invites you to mark Annals of Oncology’s 35th Anniversary by exploring significant milestones with the Milestones Monday series, the #DYK post series, exclusive interviews with Editors-in-Chief, and the 2023 most-cited papers 🔗 ow.ly/8rwR50U6a4t

📢New guidelines in press - Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up linkinghub.elsevier.com/retrieve/pii...

Stay up to date with the very latest from Annals of Oncology. Register for free to receive content and issue alerts by e-mail bit.ly/2WfW9Cb or subscribe to our RSS bit.ly/2yRH9Cp

I’m thrilled to announce the launch of ESMO Rare Cancers! This new journal aims to enhance the understanding and management of rare malignancies. Join us in sharing impactful research and improving patient outcomes. Learn more: spkl.io/8283

Discover the latest in real world data and digital oncology in ESMO Real World Data and Digital Oncology. Read our groundbreaking article, 'Equitable access to oncology clinical trials: harnessing technology to reduce geographic disparities' spkl.io/6012fuqYm

What are pragmatic clinical trials? New commentary in ESMO Real World Data and Digital Oncology explores how they use #realworld data to generate evidence. ➡️ spkl.io/6019fRzXH

Check out this month’s highlights from the European Society of Medical Oncology titles! www.esmojournals.org